Infant vaccine co-administration: review of 18 years of experience with GSK’s hexavalent vaccine co-administered with routine childhood vaccines

References

• World Health Organization. WHO vaccine-preventable diseases: monitoring system, 2019 global summary. Immunization schedule by disease covered by antigens within age range selection centre; [cited 2020 Jan 29]. Available from: https://apps.who.int/immunization_monitoring/globalsummary/diseases
   Google Scholar
• General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011;60(2):1–64.
   Google Scholar
• Kalies H, Grote V, Verstraeten T, et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–512.
   PubMed Web of Science ®Google Scholar
• Happe LE, Lunacsek OE, Kruzikas DT, et al. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J. 2009;28(2):98–101.
   PubMed Web of Science ®Google Scholar
• Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496–500.
   PubMed Web of Science ®Google Scholar
• Maman K, Zöllner Y, Greco D, et al. The value of childhood combination vaccines: from beliefs to evidence. Hu Vacc Immunother. 2015;11(9):2132–2141.
   PubMed Web of Science ®Google Scholar
• Van Hoof J. Manufacturing issues related to combining different antigens: an industry perspective. Clin Infect Dis. 2001;33(Suppl 4):S346–350.
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A review. Vaccine. 2010;28(34):5513–5523.
   PubMed Web of Science ®Google Scholar
• Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009;28(4 Suppl):S97–S108.
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines. 2008;7(1):97–115.
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R. Interactions of conjugate vaccines and co-administered vaccines. Hum Vaccin Immunother. 2016;12(1):226–230.
   PubMed Web of Science ®Google Scholar
• Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine. 2011;29(31):4881–4890.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Infanrix hexa product information. [cited 2019 Sept 6]. Available from: https://www.ema.europa.eu/en/documents/product-information/infanrix-hexa-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Hexaxim product information. [cited 2020 Jan 29]. Available from: https://www.ema.europa.eu/documents/medicine-outside-eu/hexaxim-h-w-2495-p46-021-assessment-report_en.pdf
   Google Scholar
• European Medicines Agency. Hexacima product information. [cited 2020 Jan 29]. Available from: https://www.ema.europa.eu/documents/product-information/hexacima-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Hexyon product information. [cited 2020 Jan 29]. Available from: https://www.ema.europa.eu/documents/product-information/hexyon-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Vaxelis product information. [cited 2020 Jan 29]. Available from: https://www.ema.europa.eu/documents/product-information/vaxelis-epar-product-information_en.pdf
   Google Scholar
• Food and Drug Administration. Vaxelis package insert. [cited 2020 Jan 29]. Available from: https://www.fda.gov/media/119465/download
   Google Scholar
• Van Der Meeren O, Kuriyakose S, Kolhe D, et al. Immunogenicity of InfanrixTM hexa administered at 3, 5 and 11 months of age. Vaccine. 2012;30(17):2710–2714.
   PubMed Web of Science ®Google Scholar
• Omenaca F, Vazquez L, Garcia-Corbeira P, et al. Immunization of preterm infants with GSK’s hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Vaccine. 2018;36(7):986–996.
   PubMed Web of Science ®Google Scholar
• Zepp F, Schmitt H-J, Cleerbout J, et al. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8(6):663–678.
   PubMed Web of Science ®Google Scholar
• Dolhain J, Janssens W, Mesaros N, et al. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer. Expert Rev Vaccines. 2018;17(6):513–524.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Vaccination schedules for individual European countries and specific age groups. [cited 2020 Jan 29]. Available from: https://www.ecdc.europa.eu/en/immunisation-vaccines/EU-vaccination-schedules
   Google Scholar
• World Health Organization. Summary of WHO position papers - recommended routine immunizations for children. [cited 2020 Jan 29]. Available from: https://www.who.int/immunization/policy/Immunization_routine_table2.pdf
   Google Scholar
• Schmitt HJ, Steul KS, Borkowski A, et al. Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. Vaccine. 2008;26(18):2242–2252.
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2006;25(8):713–720.
   PubMed Web of Science ®Google Scholar
• Szenborn L, Czajka H, Brzostek J, et al. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age. Pediatr Infect Dis J. 2013;32(7):777–785.
   PubMed Web of Science ®Google Scholar
• Thollot F, Scheifele D, Pankow-Culot H, et al. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age. Pediatr Infect Dis J. 2014;33(12):1246–1254.
   PubMed Web of Science ®Google Scholar
• Habermehl P, Leroux-Roels G, Sänger R, et al. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2, 3, 4 months schedule with a fourth dose at 12-18 months of age. Hum Vaccines. 2010;6(8):640–651.
   PubMed Web of Science ®Google Scholar
• Merino Arribas JM, Carmona Martinez A, Horn M, et al. Safety and Immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants: an open, randomized trial. Pediatr Infect Dis J. 2017;36(4):e98–e107.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Desole MG, et al. A combined haemophilus influenzae type b-neisseria meningitidis serogroup C-Tetanus Toxoid conjugate vaccine (Hib-MenC-TT) is Immunogenic and well-tolerated when co-administered with DTPa-HBV-IPV at 3, 5, and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J. 2013;32:521–529.
   PubMed Web of Science ®Google Scholar
• Esposito S, Prymula R, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hu Vacc Immunother. 2014;10(7):2005–2014.
   PubMed Web of Science ®Google Scholar
• Lagos RE, Munoz AE, Levine MM, et al. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin. 2011;7(5):511–522.
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, Francois N, et al. Immunogenicity, safety and reactogenicity of a booster dose of the 10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine coadministered with DTPa-IPV-Hib in Dutch children: a randomized controlled trial. Pediatr Infect Dis J. 2016;35(7):e206–219.
   PubMed Web of Science ®Google Scholar
• Lin TY, Lu CY, Chang LY, et al. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan. J Formos Med Assoc. 2012;111(9):495–503.
   PubMed Web of Science ®Google Scholar
• Wijmenga-Monsuur AJ, van Westen E, Knol MJ, et al. Direct comparison of immunogenicity induced by 10- or 13-valent pneumococcal conjugate vaccine around the 11-month booster in Dutch infants. PLoS One. 2015;10(12):e0144739.
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Guerrero ML, Hernandez-Delgado L, et al. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccin. 2011;7(11):1137–1145.
   PubMed Web of Science ®Google Scholar
• Huu TN, Toan NT, Tuan HM, et al. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial. BMC Infect Dis. 2013;13:95.
   PubMed Web of Science ®Google Scholar
• Prymula R, Szenborn L, Silfverdal SA, et al. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants. Vaccine. 2017;35(35Pt B):4603–4611.
   PubMed Web of Science ®Google Scholar
• Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin vaccin immunol. 2010;17(6):1017–1026.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, et al. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Pediatr Infect Dis J. 2012;31(4):392–399.
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28(25):4192–4203.
   PubMed Web of Science ®Google Scholar
• Gimenez-Sanchez F, Kieninger DM, Kueper K, et al. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(35):6042–6048.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Becker T, Vertruyen AF, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36(2):209–215.
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Omeñaca F, García-Sicilia J, et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2004;23(12):1109–1115.
   PubMed Web of Science ®Google Scholar
• Tejedor J-C, Omeñaca F, García-Sicilia J, et al. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age. Pediatr Infect Dis J. 2006;25(10):943–945.
   PubMed Web of Science ®Google Scholar
• Merino Arribas JM, Carmona Martinez A, Horn M, et al. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV when coadministered with MenACWY-TT in infants: results of an open, randomized trial. Pediatr Infect Dis J. 2018;37(7):704–714.
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011;29(25):4264–4273.
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu L-M, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–582.
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase ii controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–1137.
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71–79.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–835.
   PubMed Web of Science ®Google Scholar
• Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel surveillance network. Clin Infect Dis. 2006;43(9):1185–1193.
   PubMed Web of Science ®Google Scholar
• Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hu Vacc Immunother. 2014;10(7):1993–2004.
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, François N, et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J. 2011;30(9):e170–178.
   PubMed Web of Science ®Google Scholar
• Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012;30(11):2024–2031.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Sy LS, Liu IL, et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013;31(22):2578–2583.
   PubMed Web of Science ®Google Scholar
• Duffy J, Weintraub E, Hambidge SJ, et al. Febrile seizure risk after vaccination in children 6 to 23 months. Pediatrics. 2016;138:1.
   Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657–e1001657.
   PubMed Web of Science ®Google Scholar
• Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009;28(4 Suppl):S109–118.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28(4 Suppl):S77–88.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Center KJ, Brzostek J et al. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. Vaccine. 2017;35(15):1926–1935.
   PubMed Web of Science ®Google Scholar
• Prymula R, Siegrist C-A, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374(9698):1339–1350.
   PubMed Web of Science ®Google Scholar
• Falup-Pecurariu O, Man SC, Neamtu ML, et al. Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: an open-label, randomized, controlled, non-inferiority trial. Hum Vaccin Immunother. 2017;13(3):649–660.
   PubMed Web of Science ®Google Scholar
• Leung AK, Robson WL. Febrile seizures. J Pediatr Health Care. 2007;21(4):250–255.
   PubMedGoogle Scholar
• Silfverdal SA, Icardi G, Vesikari T, et al. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months. Vaccine. 2016;34(33):3810–3816.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine. 2010;28(32):5272–5279.
   PubMed Web of Science ®Google Scholar
• Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J. 2009;28(3):177–181.
   PubMed Web of Science ®Google Scholar
• Zepp F, Behre U, Kindler K, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr. 2007;166(8):857–864.
   PubMed Web of Science ®Google Scholar
• Deichmann KA, Ferrera G, Tran C, et al. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad (R)) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants. Vaccine. 2015;33(20):2379–2386.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Lindblad N, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J. 2010;29(6):e47–56.
   PubMed Web of Science ®Google Scholar
• Orsi A, Azzari C, Bozzola E, et al. Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts. J Prev Med Hyg. 2018;59(2):E107–E119.
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control. Annual epidemiological report for 2017. Diphtheria; [cited 2020 Jan 21]. Available from: https://ecdc.europa.eu/en/publications-data/diphtheria-annual-epidemiological-report-2017
   Google Scholar
• European Centre for Disease Prevention and Control. Tetanus - annual epidemiological report for 2017. [cited 2020 Jan 21]. Available from https://ecdc.europa.eu/en/publications-data/tetanus-annual-epidemiological-report-2017.
   Google Scholar
• European Centre for Disease Prevention and Control. Hepatitis B - annual epidemiological report for 2017; [cited 2020 Jan 21]. Available from: https://ecdc.europa.eu/en/publications-data/hepatitis-b-annual-epidemiological-report-2017.
   Google Scholar
• European Centre for Disease Prevention and Control. Annual epidemiological report for 2017. Pertussis; [cited 2020 Jan 21]. Available from: https://ecdc.europa.eu/en/publications-data/pertussis-annual-epidemiological-report-2017
   Google Scholar
• Sealey KL, Belcher T, Preston A. Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence. Infect Genet Evol. 2016;40:136–143.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Annual epidemiological report for 2017. Poliomyelitis; [cited 2020 Jan 21]. Available from: https://www.ecdc.europa.eu/en/publications-data/poliomyelitis-annual-epidemiological-report-2017
   Google Scholar
• European Centre for Disease Prevention and Control. Haemophilus influenzae - annual epidemiological report for 2017. [cited 2020 Jan 21]. Available from: https://www.ecdc.europa.eu/en/publications-data/haemophilus-influenzae-annual-epidemiological-report-2017
   Google Scholar
• Collins S, Ramsay M, Campbell H, et al. Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination? Clin Infect Dis. 2013;57(12):1715–1721.
   PubMed Web of Science ®Google Scholar
• Offit PA, Quarles J, Gerber MA, et al. Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics. 2002;109(1):124–129.
   PubMed Web of Science ®Google Scholar
• Nicoli F, Appay V. Immunological considerations regarding parental concerns on pediatric immunizations. Vaccine. 2017;35(23):3012–3019.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews N, Waight P, et al. Bacterial infections, immune overload, and MMR vaccine. Measles, mumps, and rubella. Arch Dis Child. 2003;88(3):222–223.
   PubMed Web of Science ®Google Scholar
• Glanz JM, Newcomer SR, Daley MF, et al. Association between estimated cumulative vaccine antigen exposure through the first 23 months of life and non-vaccine-targeted infections from 24 through 47 months of age. JAMA. 2018;319(9):906–913.
   PubMed Web of Science ®Google Scholar
• Stowe J, Andrews N, Taylor B, et al. No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine. 2009;27(9):1422–1425.
   PubMed Web of Science ®Google Scholar
• Summary of Product Characterstics. Hexyon. [ updated 22 May 2018; cited 2019 Feb 27]. Available from: https://www.ema.europa.eu/documents/product-information/hexyon-epar-product-information_en.pdf
   Google Scholar